scholarly journals Effect of Alpha-lipoic Acid Supplementation on Glycemic Control in the Patients with Metabolic Syndrome: A Randomized Clinical Trial

2020 ◽  
Author(s):  
Nafiseh Kaviyani ◽  
Seyed Ali Keshavarz ◽  
Behnood Abbasi
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Glycemic Control ◽  
Lipoic Acid ◽  
Serum Insulin ◽  
Alpha Lipoic Acid ◽  
Acid Supplementation ◽  
Positive Effects ◽  
Significant Difference

Abstract BackgroundMetabolic syndrome is a collection of metabolic disorders. It is an important risk factor for progression towards type 2 diabetes and coronary artery diseases. Alpha-lipoic acid also plays a role as a co-factor for multi-enzyme complexes catalyzing oxidative. Antioxidant properties of alpha-lipoic acid (ALA) are associated with insulin-like effects. The present study examined the effect of alpha-lipoic acid supplementation on glycemic control in the patients with metabolic syndrome.MethodsA total of 46 patients with metabolic syndrome have participated in this double-blind randomized parallel-group clinical trial, 23 patients in one group received 600 mg of alpha-lipoic acid supplement and 23 patients in another group received the placebo for 12 weeks. RCT protocol was registered at ClinicalTrials.gov and it is available using NCT03589690 code. Fasting blood sugar (FBS), Serum insulin, Hemoglobin A1c (HbA1c), insulin resistance, were measured at the beginning and the end of the study. Dietary intake of participants was examined at the beginning of the study and this information was evaluated using Nutritionist 4 (N4) software. Studied information was analyzed by SPSS-24 software.ResultsThere were significant decreases in FBS levels (P = 0.009), serum insulin (P = 0.02), and insulin resistance (P = 0.001) between the two groups. Also, the HbA1c levels (P = 0.16) had no significant difference between the two groups.ConclusionALA is a potent antioxidant that it might be able to improve the blood glucose levels, serum insulin and insulin resistance; thus it will have positive effects on promoting the health levels in the patients with metabolic syndrome.Trial registrationNCT03589690

scholarly journals Effects of Alpha-Lipoic Acid Supplementation on Cardiovascular Disease Risk Factors in β-Thalassemia Major Patients: A Clinical Trial Crossover Study

2020 ◽  
Vol Volume 11 ◽  
pp. 131-139 ◽  
Author(s):  
Khadijeh Jamshidi ◽  
Hadi Abdollahzad ◽  
Mostafa Nachvak ◽  
Mansour Rezaei ◽  
Mohammad Reza Golpayegani ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Clinical Trial ◽  
Crossover Study ◽  
Lipoic Acid ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Thalassemia Major ◽  
Alpha Lipoic Acid ◽  
Acid Supplementation

Investigation of the Association Between Carotid Artery Intima-Media Thickness (IMT) and Cardiac Risk Factors in Patients with Systemic Lupus Erythematosus

2020 ◽  
Vol 16 (2) ◽  
pp. 125-133
Author(s):  
Zahra Rezaieyazdi ◽  
Sima Sedighi ◽  
Masoumeh Salari ◽  
Mohammadreza H. Fard ◽  
Mahmoud R. Azarpazhooh ◽  
...  
Keyword(s):  
Risk Factors ◽  
Insulin Resistance ◽  
Lupus Erythematosus ◽  
Serum Insulin ◽  
Venous Blood ◽  
Test Group ◽  
Control Groups ◽  
Significant Difference ◽  
The Mean ◽  
And Control

Background: The relationship between SLE and traditional risk factors for cardiovascular events was evaluated. Methods: The data regarding sixty patients with SLE and 30 healthy controls (age and sex matched) were gathered using SLEDAI forms. Venous blood (10mL) from all the participants was examined for hs-CRP, homocysteine, VCAM1, CBC, anti-DNA antibody, C3, C4, low-density lipoprotein (LDL), cholesterol, FBS and triglyceride. : The IMT of carotid arteries was determined bilaterally by ultrasound. Other measurements included insulin levels via Elisa (Linco/Millipore Corp) and the HOMA-IR index for insulin resistance. Results: The mean age (in years) in the test and control groups was 28.8±10.3 (18-52) and 33.8±9.13 (18-48), respectively. Results: The mean age (in years) in the test and control groups was 28.8±10.3 (18-52) and 33.8±9.13 (18-48), respectively. : The average IMT in the test group was directly related to serum levels of VCAM1 (p<0.001), homocysteine (p<0.001), cholesterol (p<0.009), LDL (p<0.001), TG (p<0.001), and FPG (p=0.004). The association between other risk factors, insulin resistance, carotid IMT and SLEDAI, was nonexistent. Mean insulin and insulin resistance levels in all the participants were 0.43±2.06 µU/mL and 0.09±0.44, respectively. There was no significant difference between the test and control groups regarding serum insulin and insulin resistance levels (p=0.42 and p=0.9, respectively). None of the risk factors, such as hsCRP, VCAM1, or homocysteine, were shown to be related to insulin resistance (p=0.6, p=0.6, p=0.09, respectively). Conclusion:: Our findings did not show an increase in the prevalence of atherosclerosis in patients with SLE. There was no association between IMT and insulin resistance. However, the former was associated with FPG, total cholesterol, LDL, TG, homocystein and VCAM1.

scholarly journals The effects of metformin plus sulfonylurea therapy on clinical features of the metabolic syndrome

2010 ◽  
Vol 63 (9-10) ◽  
pp. 611-615 ◽  
Author(s):  
Branka Koprivica ◽  
Teodora Beljic-Zivkovic ◽  
Tatjana Ille
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Waist Circumference ◽  
Glycemic Control ◽  
Body Mass ◽  
Combined Therapy

Introduction. Insulin resistance is a well-known leading factor in the development of metabolic syndrome. The aim of this study was to evaluate metabolic effects of metformin added to sulfonylurea in unsuccessfully treated type 2 diabetic patients with metabolic syndrome. Material and methods. A group of thirty subjects, with type 2 diabetes, secondary sulfonylurea failure and metabolic syndrome were administered the combined therapy of sulfonylurea plus metformin for six months. Metformin 2000 mg/d was added to previously used sulfonylurea agent in maximum daily dose. Antihypertensive and hypolipemic therapy was not changed. The following parameters were assessed at the beginning and after six months of therapy: glycemic control, body mass index, waist circumference, blood pressure, triglycerides, total cholesterol and its fractions, homeostatic models for evaluation of insulin resistance and secretion (HOMA R, HOMA B) and C- peptide. Results. Glycemic control was significantly improved after six months of the combined therapy: (fasting 7.89 vs. 10.61 mmol/l. p<0.01; postprandial 11.12 vs. 12.61 mmol/l. p<0.01, p<0.01; glycosylated hemoglobin 6.81 vs. 8.83%. p<0.01). the body mass index and waist circumference were significantly lower (26.7 vs. 27.8 kg/m2, p<0.01 and 99.7 vs. 101.4 cm for men, p<0.01; 87.2 vs. 88.5 for women, p<0.01). Fasting plasma triglycerides decreased from 3.37 to 2.45 mmol/l (p<0.001) and HOMA R from 7.04 to 5.23 (p<0.001). No treatment effects were observed on blood pressure, cholesterol, and residual insulin secretion. Conclusion. Administration of metformin in type 2 diabetes with metabolic syndrome decreased cardiovascular risk factors by reducing glycemia, triglycerides, BMI, central obesity and insulin resistance.

Alpha-Lipoic Acid Shows Promise to Improve Migraine in Patients with Insulin Resistance: A 6-Month Exploratory Study

2018 ◽  
Vol 21 (3) ◽  
pp. 269-273 ◽  
Author(s):  
Cinzia Cavestro ◽  
Giorgio Bedogni ◽  
Filippo Molinari ◽  
Silvia Mandrino ◽  
Eugenia Rota ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Lipoic Acid ◽  
Exploratory Study ◽  
Alpha Lipoic Acid

The effect of alpha lipoic acid supplementation on sperm functions in idiopathic asthenozoospermic patients: a case-controlled study

2022 ◽  
pp. 1-9
Author(s):  
Yahya M. Hodeeb ◽  
Emad M. El-Rewiny ◽  
Abdullah M. Gaafar ◽  
Ahmed N. Zayed ◽  
Mohamed S. Hasan ◽  
...  
Keyword(s):  
Lipoic Acid ◽  
Controlled Study ◽  
Alpha Lipoic Acid ◽  
Acid Supplementation ◽  
Sperm Functions
Sign in / Sign up

Export Citation Format

Share Document